Latest RIDGEFIELD Stories
-- Data show initial therapy in newly diagnosed NVAF patients diverged from guideline recommendations RIDGEFIELD, Conn., March 16, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals,
-- First BLA submission for an investigational reversal agent for a novel oral anticoagulant RIDGEFIELD, Conn., March 2, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
- Less than 1 in 3 patients and caregivers are prepared for how IPF will affect their daily life RIDGEFIELD, Conn., Feb.
Only prescription medication in U.S. to combine the dual mechanisms of action of SGLT2 and DPP-4 inhibitors to improve glycemic control as an adjunct to diet and exercise RIDGEFIELD, Conn.
New choice between mist and dry powder inhalers for tiotropium RIDGEFIELD, Conn., Jan. 21, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
- Results from two large trials individually showed an improvement in the secondary endpoint of overall survival for patients with the most common EGFR mutation (Del19) RIDGEFIELD, Conn., Jan.
Tell your story concisely, consistently, interestingly Ridgefield, Connecticut (PRWEB) December 30, 2014 To gain market position, start-ups and medium-sized
- Phase I study results presented at American Society of Hematology Annual Meeting RIDGEFIELD, Conn., Dec. 8, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
- Retrospective analysis of more than 38,000 patients shows PRADAXA is associated with lower rates of stroke and major bleeding compared to warfarin RIDGEFIELD, Conn., Nov.
- Effects of idarucizumab on an exploratory marker of blood clotting, presented at the American Heart Association's Scientific Sessions RIDGEFIELD, Conn., Nov.
- Large; stout; burly.